- Hovione has completed a $100 million investment cycle to expand its spray drying and manufacturing operations in East Windsor, New Jersey, doubling its U.S. capacity.
- The expansion supports increased demand for amorphous solid dispersion (ASD) development and GMP commercial production, with operations set to begin in Q2 2026.
Hovione has completed a $100 million investment cycle to expand its U.S. manufacturing operations in East Windsor, New Jersey, doubling its spray drying capacity to meet growing market demand for amorphous solid dispersion (ASD) development and contract manufacturing.
The first phase of the expansion adds a new 31,000-square-foot facility housing two size-3 spray dryers (PSD-3). GMP operations are scheduled to commence in the second quarter of 2026. The investment enhances Hovione’s ability to deliver good manufacturing practice (GMP) production of drug substances and finished products.
As part of its growth strategy, Hovione has also acquired 15 acres of neighbouring land to support future expansion. The greenfield site will provide additional capacity for PSD-4–scale commercial production, as well as tableting, logistics, quality control, and R&D facilities.
Hovione’s U.S. operations form part of its global network spanning Portugal, Ireland, and Macau. The CDMO’s integrated service model unifies process development and commercial manufacturing under a single governance framework, supporting its “one site, one partner” approach to drug development and production.
By expanding its spray drying throughput, Hovione aims to address the increasing demand for solubility enhancement of poorly water-soluble drug candidates. The company provides particle engineering and spray drying services across all scales, from gram-level development to large-scale commercial manufacturing.
